Posts by Mourabit Halima

During the 2026 European Association of Urology (EAU) Congress, Prof. Saad M.A. from the Department of Medical Oncology at the Mohammed V Military Teaching Hospital, Rabat, Morocco, presented a systematic review and reconstructed Individual Patient Data (IPD) meta-analysis. The study evaluated the clinical value of Bacillus Calmette-Guérin (BCG) combined with Immune Checkpoint Inhibitors (ICIs) in BCG-naive patients with high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC).

During a recent academic session, Professor Dingwei Ye (Prof. Dingwei Ye) from Fudan University Shanghai Cancer Center provided an in-depth interpretation of the Phase 1/2 clinical study data for SIM0237—an anti-PD-L1/IL-15 variant fusion protein—specifically in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

During the recent ASCO GU 2025 (Genitourinary Cancers Symposium), Professor Jiwei Huang from Renji Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine (on behalf of the research team led by Ding Yingjie), presented the updated efficacy and safety data from a multicenter, single-arm, Phase II trial. The study evaluates the combination of Fruquintinib and Serplulimab as a first-line (1st-line) treatment for patients with metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC).

During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC) who are at risk of BCG-unresponsiveness or disease progression following treatment.

At a recent international uro-oncology symposium, Dr. Takemura K. from the Department of Genitourinary Oncology at the Japanese Foundation for Cancer Research (JFCR), Ariake Hospital, presented findings from a multicenter retrospective study investigating the correlation between the time-of-day administration (ToDA) of first-line immune checkpoint inhibitors (ICIs) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

During a recent academic session, Dr. Tao Zihao from Peking University First Hospital presented the preliminary results of a Phase II study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in combination with radiotherapy for the adjuvant treatment of Upper Tract Urothelial Carcinoma (UTUC). This study provides a potential new therapeutic strategy for high-risk UTUC patients who are cisplatin-ineligible or refuse conventional chemotherapy

At a recent academic symposium, Dr. Xuanjun Guo (Peking University First Hospital) presented data from a multicenter real-world study evaluating the efficacy and safety of Disitamab Vedotin (RC48), a humanized anti-HER2 antibody-drug conjugate (ADC), administered as monotherapy or in combination with PD-1 inhibitors for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). This study provides critical real-world evidence for patients seeking bladder-sparing alternatives.

The 2026 ASCO Genitourinary Cancers Symposium (ASCO-GU) recently concluded successfully in San Francisco, USA. As one of the most influential global academic conferences in the field of genitourinary oncology, the meeting brings together the latest research advances and evolving clinical perspectives from around the world.

For patients with end-stage kidney disease, kidney transplantation represents a life-changing treatment that can restore quality of life and offer a “second chance.” However, transplantation success is only the beginning of a long journey. Lifelong immunosuppressive therapy—while essential for preventing rejection—also exposes recipients to a significant risk: infection.

The concept of synthetic lethality, achieved through PARP inhibitors (PARPi), has ushered in the era of precision therapy for prostate cancer. Clinical studies evaluating PARPi either as monotherapy or in combination with next-generation androgen receptor pathway inhibitors (ARPI), such as PROfound and PROpel, have already produced landmark advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC).